On Friday, Acrivon Therapeutics Inc (NASDAQ: ACRV) was -4.91% drop from the session before settling in for the closing price of $9.98. A 52-week range for ACRV has been $3.19 – $12.52.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 11.47%. With a float of $21.68 million, this company’s outstanding shares have now reached $22.52 million.
The firm has a total of 58 workers. Let’s measure their productivity. In terms of profitability, gross margin is 52.02%, operating margin of -4049.63%, and the pretax margin is -3662.53%.
Acrivon Therapeutics Inc (ACRV) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Acrivon Therapeutics Inc stocks. The insider ownership of Acrivon Therapeutics Inc is 29.99%, while institutional ownership is 68.94%. The most recent insider transaction that took place on Apr 11 ’24, was worth 20,000,500. In this transaction 10% Owner of this company bought 2,353,000 shares at a rate of $8.50, taking the stock ownership to the 5,360,858 shares.
Acrivon Therapeutics Inc (ACRV) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.66 earnings per share (EPS) during the time that was better than consensus figure (set at -0.71) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.61 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.47% per share during the next fiscal year.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Trading Performance Indicators
You can see what Acrivon Therapeutics Inc (ACRV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 16.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.77, a number that is poised to hit -0.58 in the next quarter and is forecasted to reach -2.65 in one year’s time.
Technical Analysis of Acrivon Therapeutics Inc (ACRV)
Analysing the last 5-days average volume posted by the [Acrivon Therapeutics Inc, ACRV], we can find that recorded value of 89320.0 was lower than the volume posted last year of 0.34 million. As of the previous 9 days, the stock’s Stochastic %D was 78.98%. Additionally, its Average True Range was 0.62.
During the past 100 days, Acrivon Therapeutics Inc’s (ACRV) raw stochastic average was set at 66.39%, which indicates a significant decrease from 79.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.75% in the past 14 days, which was lower than the 84.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.65, while its 200-day Moving Average is $6.43. Now, the first resistance to watch is $10.13. This is followed by the second major resistance level at $10.76. The third major resistance level sits at $11.37. If the price goes on to break the first support level at $8.89, it is likely to go to the next support level at $8.28. Should the price break the second support level, the third support level stands at $7.65.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Key Stats
There are 30,877K outstanding shares of the company, which has a market capitalization of 293.91 million. As of now, sales total 0 K while income totals -60,390 K. Its latest quarter income was 0 K while its last quarter net income were -18,800 K.
